Abeona Therapeutics (NASDAQ:ABEO) Upgraded at StockNews.com

StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a sell rating to a hold rating in a research note published on Friday morning.

ABEO has been the subject of a number of other reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $18.00 price target on shares of Abeona Therapeutics in a research report on Tuesday, October 29th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a research report on Monday, November 25th.

Abeona Therapeutics Trading Up 1.5 %

Shares of ABEO stock opened at $6.02 on Friday. The firm has a 50 day moving average price of $5.66 and a two-hundred day moving average price of $5.79. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $261.69 million, a PE ratio of -2.24 and a beta of 1.43. Abeona Therapeutics has a 12-month low of $3.05 and a 12-month high of $9.01.

Institutional Investors Weigh In On Abeona Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new stake in Abeona Therapeutics during the third quarter worth $84,000. Oxford Asset Management LLP acquired a new position in shares of Abeona Therapeutics during the fourth quarter worth $118,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Abeona Therapeutics during the third quarter worth $151,000. XTX Topco Ltd acquired a new position in shares of Abeona Therapeutics during the third quarter worth $160,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in shares of Abeona Therapeutics during the fourth quarter worth $341,000. 80.56% of the stock is currently owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.